SG10201806715TA - Use of inos inhibitors to increase viral yield in culture - Google Patents
Use of inos inhibitors to increase viral yield in cultureInfo
- Publication number
- SG10201806715TA SG10201806715TA SG10201806715TA SG10201806715TA SG10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA
- Authority
- SG
- Singapore
- Prior art keywords
- culture
- inos inhibitors
- viral yield
- increase viral
- increase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000003612 virological effect Effects 0.000 title abstract 2
- 101100396994 Drosophila melanogaster Inos gene Proteins 0.000 title 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 abstract 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 abstract 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- GIXWDMTZECRIJT-UHFFFAOYSA-N aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
- 229960000604 valproic acid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361750175P | 2013-01-08 | 2013-01-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201806715TA true SG10201806715TA (en) | 2018-09-27 |
Family
ID=51167323
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201806715TA SG10201806715TA (en) | 2013-01-08 | 2014-01-07 | Use of inos inhibitors to increase viral yield in culture |
SG11201505333PA SG11201505333PA (en) | 2013-01-08 | 2014-01-07 | Use of inos inhibitors to increase viral yield in culture |
SG10201913130PA SG10201913130PA (en) | 2013-01-08 | 2014-01-07 | Use of inos inhibitors to increase viral yield in culture |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201505333PA SG11201505333PA (en) | 2013-01-08 | 2014-01-07 | Use of inos inhibitors to increase viral yield in culture |
SG10201913130PA SG10201913130PA (en) | 2013-01-08 | 2014-01-07 | Use of inos inhibitors to increase viral yield in culture |
Country Status (20)
Country | Link |
---|---|
US (2) | US11299715B2 (ja) |
EP (3) | EP3521420A1 (ja) |
JP (2) | JP6534933B2 (ja) |
KR (1) | KR102307279B1 (ja) |
CN (1) | CN105008523B (ja) |
AR (1) | AR094389A1 (ja) |
AU (1) | AU2014205604B2 (ja) |
BR (2) | BR122020002822B1 (ja) |
CA (1) | CA2897444A1 (ja) |
DK (1) | DK2943567T3 (ja) |
ES (1) | ES2651763T3 (ja) |
HK (2) | HK1214840A1 (ja) |
HU (1) | HUE037482T2 (ja) |
IL (1) | IL239824B (ja) |
MX (1) | MX360470B (ja) |
NO (1) | NO3050055T3 (ja) |
RU (1) | RU2676733C2 (ja) |
SG (3) | SG10201806715TA (ja) |
TW (1) | TWI608102B (ja) |
WO (1) | WO2014110053A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
AU2015346162B2 (en) | 2014-11-14 | 2022-02-10 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
ES2878451T3 (es) | 2014-11-14 | 2021-11-18 | Voyager Therapeutics Inc | Polinucleótidos moduladores |
WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
PL3436593T3 (pl) | 2016-03-28 | 2023-03-27 | Ultragenyx Pharmaceutical Inc. | Sposoby inaktywacji termicznej adenowirusów |
AU2017267665C1 (en) | 2016-05-18 | 2023-10-05 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
EP3526321A4 (en) | 2016-10-14 | 2020-05-13 | Ultragenyx Pharmaceutical Inc. | USE OF TONIFYING AGENTS TO IMPROVE THE YIELD OF RECOMBINANT ADENO-ASSOCIATED VIRUS |
WO2018175775A1 (en) | 2017-03-22 | 2018-09-27 | Dimension Therapeutics | Cell culture methods involving hdac inhibitors or rep proteins |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
CN110835622B (zh) * | 2018-08-16 | 2021-04-27 | 上海药明生物技术有限公司 | 用于调节哺乳动物细胞乳酸代谢的培养基及其应用 |
EP4121520A1 (en) | 2020-03-16 | 2023-01-25 | Ultragenyx Pharmaceutical Inc. | Methods for enhancing recombinant adeno-associated virus yield |
CN118871575A (zh) * | 2022-02-21 | 2024-10-29 | 学校法人日本医科大学 | 病毒载体生产增强剂及产生病毒载体的方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
RU2012335C1 (ru) | 1991-07-04 | 1994-05-15 | Уфимский научно-исследовательский институт глазных болезней | Ингибитор вируса простого герпеса |
JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
CA2141574C (en) | 1992-07-31 | 2009-11-24 | David Knipe | Herpesvirus vaccines |
US7223411B1 (en) | 1992-07-31 | 2007-05-29 | Dana-Farber Cancer Institute | Herpesvirus replication defective mutants |
US6833271B2 (en) | 1996-12-04 | 2004-12-21 | Medi-Cult A/S | Serum-free cell culture media |
GB9816856D0 (en) | 1998-08-03 | 1998-09-30 | Univ London | Cell lines for virus growth |
US6783972B1 (en) * | 1998-09-22 | 2004-08-31 | University Of Florida Research Foundation | Methods for large-scale production of recombinant AAV vectors |
US6593123B1 (en) | 2000-08-07 | 2003-07-15 | Avigen, Inc. | Large-scale recombinant adeno-associated virus (rAAV) production and purification |
US7091029B2 (en) | 2002-09-23 | 2006-08-15 | Applied Genetics Technologies Corporation | High titer recombinant AAV production |
US7427396B2 (en) | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
CN100348718C (zh) * | 2005-10-18 | 2007-11-14 | 中国人民解放军军事医学科学院生物工程研究所 | 一种支持hek293细胞贴附培养的无动物来源成分无血清培养基 |
US8334295B2 (en) * | 2007-06-29 | 2012-12-18 | Korea Research Institute Of Chemical Technology | Pyrimidine derivatives as HIV reverse transcriptase inhibitors |
-
2014
- 2014-01-07 US US14/758,785 patent/US11299715B2/en active Active
- 2014-01-07 RU RU2015133205A patent/RU2676733C2/ru active
- 2014-01-07 TW TW103100466A patent/TWI608102B/zh active
- 2014-01-07 CN CN201480012376.2A patent/CN105008523B/zh active Active
- 2014-01-07 EP EP19160865.2A patent/EP3521420A1/en not_active Withdrawn
- 2014-01-07 HU HUE14703459A patent/HUE037482T2/hu unknown
- 2014-01-07 AU AU2014205604A patent/AU2014205604B2/en not_active Ceased
- 2014-01-07 MX MX2015008861A patent/MX360470B/es active IP Right Grant
- 2014-01-07 ES ES14703459.9T patent/ES2651763T3/es active Active
- 2014-01-07 DK DK14703459.9T patent/DK2943567T3/en active
- 2014-01-07 JP JP2015551846A patent/JP6534933B2/ja active Active
- 2014-01-07 SG SG10201806715TA patent/SG10201806715TA/en unknown
- 2014-01-07 SG SG11201505333PA patent/SG11201505333PA/en unknown
- 2014-01-07 KR KR1020157021175A patent/KR102307279B1/ko active IP Right Grant
- 2014-01-07 WO PCT/US2014/010553 patent/WO2014110053A1/en active Application Filing
- 2014-01-07 EP EP14703459.9A patent/EP2943567B1/en active Active
- 2014-01-07 BR BR122020002822-0A patent/BR122020002822B1/pt active IP Right Grant
- 2014-01-07 CA CA2897444A patent/CA2897444A1/en not_active Abandoned
- 2014-01-07 BR BR112015016328-9A patent/BR112015016328B1/pt active IP Right Grant
- 2014-01-07 SG SG10201913130PA patent/SG10201913130PA/en unknown
- 2014-01-07 EP EP17184746.0A patent/EP3266866B1/en active Active
- 2014-01-08 AR ARP140100065A patent/AR094389A1/es unknown
- 2014-09-26 NO NO14781027A patent/NO3050055T3/no unknown
-
2015
- 2015-07-07 IL IL239824A patent/IL239824B/en active IP Right Grant
-
2016
- 2016-03-10 HK HK16102764.2A patent/HK1214840A1/zh unknown
-
2018
- 2018-07-10 HK HK18108963.6A patent/HK1249544A1/zh unknown
-
2019
- 2019-05-28 JP JP2019098958A patent/JP6837094B2/ja active Active
-
2022
- 2022-03-03 US US17/686,245 patent/US20220340883A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201806715TA (en) | Use of inos inhibitors to increase viral yield in culture | |
MX2020003096A (es) | Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif. | |
NZ704662A (en) | Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid | |
MY181688A (en) | Improved production of fatty acid derivatives | |
EP2808318A4 (en) | CRYSTALLINE FORM OF PROSTAGLANDIN ANALOGUE, PROCESS FOR PREPARING SAME AND USE THEREOF | |
EP2803657A4 (en) | CRYSTAL FORM OF PROSTAGLANDINANALOGA AND METHOD OF PREPARING THEREOF AND USE THEREOF | |
MX371093B (es) | Compuestos de microarn y metodos para modular al mir-122. | |
PH12016500500A1 (en) | A viral vaccine and methods of manufacture thereof | |
MX365302B (es) | Métodos de monitoreo terapéutico del gliceril tri- [ 4-fenilbutirato] (hpn-100) para usarse en el tratamiento de trastornos de retención de nitrógeno. | |
IN2014DN07958A (ja) | ||
MX2015012580A (es) | El uso de sdf-1 para atenuar la formacion de cicatrices. | |
MD20130073A2 (en) | New crystal form VII of agomelatine, preparation method and use thereof, and pharmaceutical composition containing the same | |
IN2013MU01431A (ja) | ||
AU2016204276A1 (en) | Methods for producing virus particles with simplified glycosylation of surface proteins | |
MX2015007945A (es) | Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas. | |
EP3242932A4 (en) | Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof | |
MX2020002286A (es) | Composicion para el tratamiento del cancer asociado con la infeccion del hpv. | |
MX2015010763A (es) | Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento. | |
WO2014115087A3 (en) | A method for the preparation of recombinant human prothrombin and fibrinogen | |
WO2015066488A3 (en) | Method for producing induced pluripotent stem cells | |
IN2014DN10683A (ja) | ||
MX353587B (es) | Formulaciones farmacéuticas que contienen ipidacrina y su uso para el tratamiento de trastornos de potencia y trastornos de otras formas de actividad sexual. | |
IN2013CH04330A (ja) | ||
IN2013MU03086A (ja) | ||
UA77066U (ru) | Способ изготовления анатомических препаратов |